Iftikhar Haq, DO
Family Medicine · Keystone Heights, FLNPI 1902899958
Payments from drug & device makers
Across 69 payments — averaging $17.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$236
- Novo Nordisk$163
- Lilly USA, LLC$137
- GSK$132
- AstraZeneca$120
- Gilead$54
- plus $352 from 13 others
What the payments were for
- Food & beverage$1,194100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 12 | $236 |
| Novo Nordisk | 10 | $163 |
| Lilly USA, LLC | 7 | $137 |
| GSK | 8 | $132 |
| AstraZeneca | 8 | $120 |
| Gilead | 3 | $54 |
| Insulet Corporation | 2 | $41 |
| Exact Sciences | 3 | $41 |
| UCB, Inc. | 1 | $39 |
| Pfizer | 3 | $38 |
| Boehringer Ingelheim | 2 | $36 |
| Merck | 2 | $30 |
| Johnson & Johnson | 2 | $27 |
| Cequr Corporation | 1 | $20 |
| Abbott | 1 | $19 |
| Biogen | 1 | $18 |
| Amgen | 1 | $15 |
| Bayer | 1 | $15 |
| Sunovion Pharmaceuticals Inc. | 1 | $13 |
How this compares
$1,194 in reported general payments places this provider in the 65th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 107 | $68,858 |
| EliquisApixaban | 72 | $56,018 |
| OzempicSemaglutide | 50 | $54,517 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 66 | $52,113 |
| TrulicityDulaglutide | 55 | $51,521 |
| JanuviaSitagliptin Phosphate | 31 | $26,156 |
| XareltoRivaroxaban | 17 | $25,688 |
| EntrestoSacubitril/Valsartan | 30 | $23,195 |
| FarxigaDapagliflozin Propanediol | 20 | $22,088 |
| Spiriva RespimatTiotropium Bromide | 35 | $19,882 |
| Tresiba Flextouch U-100Insulin Degludec | 34 | $13,651 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 23 | $13,519 |
| Breo ElliptaFluticasone/Vilanterol | 32 | $12,667 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 109 | $12,166 |
| SymbicortBudesonide/Formoterol Fumarate | 26 | $9,009 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Spiriva Respimat | $36 | $88,740142 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Shingrix, Arnuity Ellipta | $132 | $71,581128 claims |
| PfizerEliquis | $38 | $56,01872 claims |
| Novo NordiskOzempic | $163 | $54,51750 claims |
| Lilly USA, LLCTrulicity | $137 | $51,52155 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $120 | $44,61669 claims |
| MerckJanuvia | $30 | $26,15631 claims |
| Johnson & JohnsonXarelto | $27 | $25,68817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Keystone Heights
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
- Dario AltamiranoHialeah$15.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.